Multiparametric Mapping for Assessment of Cancer Therapy Related Cardiotoxicity
|
|
- Kristina Tate
- 5 years ago
- Views:
Transcription
1 Multiparametric Mapping for Assessment of Cancer Therapy Related Cardiotoxicity Cory V. Noel, M.D. Medical Director of CMR Pediatric Cardiology
2 Outline What is meant by the term cardiotoxicity? Scope of the issue of cardiotoxicity Current guidelines for cardiotoxicity detection Advantages of CMR in the identification of cardiotoxicity Integration of CMR into surveillance imaging Page 1 xxx00.#####.ppt 10/11/2017 8:58:56 AM
3 Cancer-Related Cardiotoxicity CV-related disease is leading cause of morbidity and mortality At 30 years of age, over 70% of survivors have chronic health condition Pediatric Cancer and Cardiotoxicity Establishment of a Cardio-Oncology Team 8 x more likely to die of heart disease 15 x more likely to develop HF Risk further increased when used with radiation therapy Oeffinger, et al., NEJM, 2006 Mertens, et al., J Clin Oncol, 2001 Landy, et al., Pediatr Cardiol, 2013d Page 2 xxx00.#####.ppt 10/11/2017 8:58:57 AM
4 Cardiotoxicity Bloom MW, et al., Circulation: Heart Failure, 2016 Page 3 xxx00.#####.ppt 10/11/2017 8:58:57 AM
5 What is meant by Cardiotoxicity? No uniform definition Primarily concerns left ventricular systolic function Commonly used definition is > 5% drop in LVEF with HF symptoms or a > 10% asymptomatic drop to an LVEF below 55% Recent expert consensus for multimodality imaging recommends a decrease to 53% Cardiotoxicity versus Cancer Therapy-Related Cardiac Dysfunction (CTRCD) Seidman, et al., J Clin Oncol, 2002 Plana, et al., JASE, 2014 Page 4 xxx00.#####.ppt 10/11/2017 8:58:57 AM
6 Defining the Issue Cardiotoxicity (NCI) Grade I: Asymptomatic biomarkers or abnormalities on imaging Grade II & III: Symptoms with mild to moderate exertion Grade IV: Severe, life threatening symptoms Grade V: Death Bloom MW, et al., Circulation: Heart Failure, 2016 CTRCD (ESC, ASE) Decrease in LVEF of > 10% to a value below 53%... Confirmed by repeat imaging Reversible if return to within 5% of baseline Partial if improved by 10%, but not within 5% of baseline Irreversible if improved <10%, and remains > 5% from baseline Page 5 xxx00.#####.ppt 10/11/2017 8:58:57 AM
7 Scope of the Issue With variable definition, true prevalence is difficult to quantify Studies often do not account for baseline risks Bloom MW, et al., Circulation: Heart Failure, 2016 Page 6 xxx00.#####.ppt 10/11/2017 8:58:57 AM
8 Timing of Cardiac Effect Acute toxicity (within 1 week) Uncommon (~1%), generally reversible Early-onset chronic form (within 1 year) Peak incidence in 3 months ( %) Typically irreversible Late-onset chronic form (after 1 year) years (1.6 5%) Typically irreversible Bloom MW, et al., Circulation: Heart Failure, 2016 Wickramasinghe CD, et al., Future Oncology, 2016 Page 7 xxx00.#####.ppt 10/11/2017 8:58:57 AM
9 Scope of the Issue Reasonable prevalence of early and late-onset chronic dysfunction Several risk factors playing a role Likely much higher prevalence of asymptomatic dysfunction that could be detected with improved surveillance Page 8 xxx00.#####.ppt 10/11/2017 8:58:57 AM
10 Importance of Early Detection St. Jude Lifetime Cohort 1853 adult survivors of childhood cancer Median age of 8 years at time of diagnosis Median age of 31 years at evaluation Mulrooney D, et al., Annals of Internal Medicine, 2016 Page 9 xxx00.#####.ppt 10/11/2017 8:58:58 AM
11 Evaluation of LV Function Curigliano, et al., Annals of Oncol, 2012 Page 10 xxx00.#####.ppt 10/11/2017 8:58:58 AM
12 Variability with Echo Assessment Plana, et al., JASE, 2014 Page 11 xxx00.#####.ppt 10/11/2017 8:58:58 AM
13 Variability of Echo Assessment Commonly used definition of > 5% drop in LVEF with HF symptoms or a > 10% asymptomatic drop to an LVEF below 55% Longitudinal variability of 2D LVEF is about 10% Page 12 xxx00.#####.ppt 10/11/2017 8:58:58 AM
14 Cardiac MRI versus Echo 114 adult survivors of childhood cancer 14% shown to have LVEF < 50% by CMR 2D echo overestimated the LVEF by 5% Armstrong, et al., J of Clin Oncol, 2012 Page 13 xxx00.#####.ppt 10/11/2017 8:58:58 AM
15 Integration of Cardiac MRI Unable to obtain accurate baseline assessment Confirmation of significant LVEF drop or value below 55% When considering holding or stopping cancerrelated therapy When complete with cancer-related therapy Risk-based intervals in long-term surveillance Page 14 xxx00.#####.ppt 10/11/2017 8:58:58 AM
16 Is There a Need for Earlier Detection? Is it possible to improve predictive analysis on which patients will develop heart failure and CTRCD? Page 15 xxx00.#####.ppt 10/11/2017 8:58:58 AM
17 Limitations of LVEF Relatively insensitive tool for detecting early damage Myocardial changes occur at doses below those typically associated with a drop in LVEF Morphological continuum of myocardial injury A drop in the LVEF appears to be a relatively late event in the cardiotoxicity cascade Ewer, et al., J of Clin Oncol, 1984 Cross, et al., Brit J of Pharm., 2015 Suter, et al., Euro Heart Journ., 2013 Page 16 xxx00.#####.ppt 10/11/2017 8:58:59 AM
18 Early Detection of Cardiac Dysfunction Allow for earlier identification of cardiac changes, particularly in cases of acute or early forms of cardiotoxicity Modify treatment regimen if needed Identify patients that may require more frequent surveillance imaging Goal to identify non-invasive imaging biomarkers to predict ventricular dysfunction Page 17 xxx00.#####.ppt 10/11/2017 8:58:59 AM
19 Importance of Early Detection Cardinale D, et al., JACC, 2010 Page 18 xxx00.#####.ppt 10/11/2017 8:58:59 AM
20 Utility of MRI in Early Detection Early anthracycline toxicity associated with inflammation, vacuolization and cardiomyocyte edema These changes occur before myocardial functional abnormalities Later stages of toxicity associated with fibrosis MRI offers the ability of myocardial characterization Regional wall deformation assessment Kajihara, et al., Pathol Res Pract, 1986 Friedman, et al., JAMA, 1978 Cottin, et al., Can J of Pharm, 1994 Page 19 xxx00.#####.ppt 10/11/2017 8:58:59 AM
21 Utility of MRI in Early Detection Cross, et al., Brit J of Pharm, 2015 Meyersohn N, et al., Curr Treat Options Cardio Med, 2015 Page 20 xxx00.#####.ppt 10/11/2017 8:58:59 AM
22 CMR Myocardial Characterization T2 T2 maps and weighted imaging is sensitive to both regional and global myocardial edema Myocardial edema occurs as a result of acute injury Edema occurs relatively early in the myocardial cascade prior to cardiomyocyte necrosis Mirakhur, et al., Euro J of Radiol, 2013 Francone, et al., Radiol Medicine, 2011 Page 21 xxx00.#####.ppt 10/11/2017 8:58:59 AM
23 CMR Myocardial Characterization T2 Mirakhur, et al., Euro J of Radiol, 2013 Thavendiranathan, et al., Circ Imaging, 2013 Page 22 xxx00.#####.ppt 10/11/2017 8:58:59 AM
24 CMR Myocardial Characterization T2 Smith et al have illustrated in 28 breast CA patients that increased SI on day 3 associated with drop in LVEF at 1 year Grover et al examined 46 breast CA patients 49% had abnormal T2 consistent with myocardial edema at 1 or 4 months after therapy commencement Thavendiranathan, et al., Circ Imaging, 2015 Grover, et al., Int J of Cardiol, 2013 Page 23 xxx00.#####.ppt 10/11/2017 8:59:00 AM
25 65 adult patients treated with anthracyclines CMR prior to and 3 months following chemo LVEF had a small but significant decline over the 3 month span (57±6% to 54±7%) T1-weighted imaging occurs diffusely and is associated with the drop in LVEF T2 imaging likely affected by timing of CMR Jordan, et al., Circ. Imaging, 2014 Page 24 xxx00.#####.ppt 10/11/2017 8:59:00 AM
26 Extracellular Volume Quantification Utilizes myocardial and blood T1 times, as well as hematocrit to calculate ECV fraction Highly accurate detection of diffuse myocardial fibrosis Moon JC, et al., JCMR, 2013 Ugander M, et al., Euro Heart J, 2012 Wong T, et al., Circulation, 2012 Page 25 xxx00.#####.ppt 10/11/2017 8:59:00 AM
27 CMR Myocardial Characterization T1 Schelbert E, et al., Radiology, 2016 Page 26 xxx00.#####.ppt 10/11/2017 8:59:01 AM
28 Extracellular Volume Quantification Shelbert E, et al., Journal of AHA, 2016 Kammerlander A, et al., JACC: Imaging, 2016 Page 27 xxx00.#####.ppt 10/11/2017 8:59:01 AM
29 CMR Myocardial Characterization T1 Jordan J, et al., Circulation: Imaging., 2016 Page 28 xxx00.#####.ppt 10/11/2017 8:59:01 AM
30 CMR Myocardial Characterization T1 Jordan J, et al., Circulation: Imaging., 2016 Page 29 xxx00.#####.ppt 10/11/2017 8:59:02 AM
31 CMR Regional Wall Motion Analysis Assessment of myocardial strain that may depict a decrease in myocardial function prior than EF Evaluation of 46 longterm childhood CA survivors Normal LVEF by echo Lower T1 values Toro-Salazar, et al., Circ Imaging, 2013 Page 30 xxx00.#####.ppt 10/11/2017 8:59:02 AM
32 Current Clinical Study 10 patients with diagnosis of solid bone tumor and expected anthracycline dose > 250 mg/m^2 CMR baseline prior to chemotherapy initiation mg/m^2 12 months following final chemotherapy administration Exercise stress test with VO2 calculation at 12 months Page 31 xxx00.#####.ppt 10/11/2017 8:59:02 AM
33 Protocol Multiplanar Survey Cine Sequences btfe VLA, 4-Chamber, SAX Volumetric and Functional Quantification LV Mass T2 and Native T1 Mapping 45 minutes SPAMM and fsenc Myocardial Deformation Rest perfusion 1.5 Dose Gadobutrol Delayed Enhancement T1 Mapping and ECV Quantification Page 32 xxx00.#####.ppt 10/11/2017 8:59:02 AM
34 Patient Page 33 xxx00.#####.ppt 10/11/2017 8:59:02 AM
35 Myocardial Characterization by CMR Page 34 xxx00.#####.ppt 10/11/2017 8:59:03 AM
36 Myocardial Characterization by CMR Page 35 xxx00.#####.ppt 10/11/2017 8:59:03 AM
37 Myocardial Characterization by CMR Page 36 xxx00.#####.ppt 10/11/2017 8:59:03 AM
38 Potential Future Incorporation of CMR Utilization for early detection based upon myocardial characterization and myocardial strain Utilization in long-term survivors for prognosis with ECV and determining future surveillance Page 37 xxx00.#####.ppt 10/11/2017 8:59:03 AM
39 Thank you Page 38 xxx00.#####.ppt 10/11/2017 8:59:03 AM
Cardio-oncology: Applying new echo technology to guide therapy
Cardio-oncology: Applying new echo technology to guide therapy Dinesh Thavendiranathan MD, SM, FRCPC, FASE Director, Ted Rogers Program in Cardiotoxicity Prevention Assistant Professor of Medicine Division
More informationHow to Evaluate the Heart of Elderly Patients
How to Evaluate the Heart of Elderly Patients Special considerations regarding cardiotoxicity Michael S. Ewer MD The University of Texas M. D. Anderson Cancer Center Why Discuss Cardiac Disease and Cancer
More informationDisclosures. Objectives. SK continued. Two of my patients. First and foremost, why is this important??? 10/26/2016
Disclosures Bayer Pharmaceuticals: clinical trial investigator KellyAnn Light-McGroary, MD, FACC Clinical Assistant Professor Cardiomyopathy Treatment Program University of Iowa Hospitals and Clinics Chief
More informationGuideline-Driven Care in Cardio- Oncology: Utilizing Recommendations Across Disciplines
Guideline-Driven Care in Cardio- Oncology: Utilizing Recommendations Across Disciplines Jennifer Liu, MD FACC FASE Director of CV Laboratories Associate Professor of Clinical Medicine Memorial Sloan Kettering
More informationCV Strategies to Mitigate Cardiotoxicity Pharmacologic Therapy Heart Failure Medications and Statins and For How Long
CV Strategies to Mitigate Cardiotoxicity Pharmacologic Therapy Heart Failure Medications and Statins and For How Long Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Albert
More informationBuilding a Cardio-Oncology Program
Building a Cardio-Oncology Program Marielle Scherrer-Crosbie, MD, PhD Professor of Medicine Director of Echocardiography University of Pennsylvania Philadelphia, PA Co-Director, Cardio-Oncology Program
More informationAdvanced Echocardiography in the Evaluation of Chemotherapy Patients
Advanced Echocardiography in the Evaluation of Chemotherapy Patients Juan Carlos Plana, MD, FACC, FASE Co-Director, Cardio-Oncology Center Section of Cardiovascular Imaging Department of Cardiovascular
More informationCancer and the heart: New evidence and open issues
Cancer and the heart: New evidence and open issues Dimitrios Farmakis, MD, PhD, FESC Assist. Professor, European University Cyprus Cardio-Oncology Clinic, Heart Failure Unit, Attikon Hospital Cardiac Clinic
More informationCardiotoxicity from Chemotherapy : From Early Predictors to Therapeutics
Cardiotoxicity from Chemotherapy : From Early Predictors to Therapeutics Richard Sheppard MD FRCPC Director of Heart Failure Research Heart Function Clinic Jewish General hospital Objectives 1. Discuss
More informationHFPEF Echo with Strain vs. MRI T1 Mapping
HFPEF Echo with Strain vs. MRI T1 Mapping Erik Schelbert, MD MS Director, Cardiovascular Magnetic Resonance Assistant Professor of Medicine Heart & Vascular Institute University of Pittsburgh Disclosures
More informationCardiotoxicity Effects of Chemotherapeutic Drugs
Cardiotoxicity Effects of Chemotherapeutic Drugs Allan L Klein M.D. Director, Center of Pericardial Diseases Professor of Medicine Heart and Vascular Institute Cleveland Clinic President, ASE * No conflicts
More informationCardio oncology Double Jeopardy
Cardio oncology Double Jeopardy Edie Pituskin RN MN (NP Adult) PhD NP Forum for Nursing and Allied Health, April 10, 2015 Aims Describe the double jeopardy faced by cancer patients Discuss issues in detection
More informationCured of Cancer but now Let s Heal the Heart An exploration into the effects of cancer on the heart
Cured of Cancer but now Let s Heal the Heart An exploration into the effects of cancer on the heart Suma H. Konety, MD, MS Associate Professor, Cardiovascular Division University of Minnesota What is Cardio-Oncology?
More informationIRM cardiaque en cancérologie: le rôle du radiologue
IRM cardiaque en cancérologie: le rôle du radiologue Laurent MACRON Centre Cardiologique du Nord (CCN) Saint Denis Centre Cardiologique du Nord - Saint Denis - France CMR in oncology Characterisation of
More informationCardiovascular Imaging Endpoints in Oncology Clinical Trials
Cardiovascular Imaging Endpoints in Oncology Clinical Trials Bonnie Ky, MD, MSCE Assistant Professor of Medicine and Epidemiology Director, Penn Cardio-Oncology Center of Excellence Director, Penn Center
More informationStrain Imaging: Myocardial Mechanics Simplified and Applied
9/28/217 Strain Imaging: Myocardial Mechanics Simplified and Applied John Gorcsan III, MD Professor of Medicine Director of Clinical Research Division of Cardiology VECTORS OF CONTRACTION Shortening Thickening
More informationCan point of care cardiac biomarker testing guide cardiac safety during oncology trials?
Can point of care cardiac biomarker testing guide cardiac safety during oncology trials? Daniel J Lenihan, MD Professor, Division of Cardiovascular Medicine Director, Clinical Research Vanderbilt University
More information03/14/2019. Scope of the Problem. Objectives
Cardiac Consideration During and After Breast Cancer Treatment Indu G. Poornima M.D Division of Cardiology Scope of the Problem 1 in 8 women will develop breast cancer 3.3 million women are survivors CVD
More informationCardio-oncology: Basics and Knowing When You Need an Echo
Cardio-oncology: Basics and Knowing When You Need an Echo Vera H. Rigolin, MD, FASE, FACC, FAHA Professor of Medicine Northwestern University Feinberg School of Medicine Medical Director, Echocardiography
More informationCardio-Oncology: Advancing Cardiovascular Care of the Oncology Patient
Cardio-Oncology: Advancing Cardiovascular Care of the Oncology Patient Vijay U. Rao, MD, PhD, FACC, FASE Franciscan Physician Network Indiana Heart Physicians Director, Franciscan Health Inpatient Heart
More informationCT for Myocardial Characterization of Cardiomyopathy. Byoung Wook Choi, Yonsei University Severance Hospital, Seoul, Korea
CT for Myocardial Characterization of Cardiomyopathy Byoung Wook Choi, Yonsei University Severance Hospital, Seoul, Korea Cardiomyopathy Elliott P et al. Eur Heart J 2008;29:270-276 The European Society
More informationCancer survivors. Half of Cancer Survivors Die of Other Conditions. Cause of Death in Cancer Survivors
Cardiotoxicity of Cancer Therapies: Pathogenesis, Diagnosis, and Management Edward T.H. Yeh, M.D. Cancer survivors Now nearly 12 million cancer survivors in U.S. according to NCI 15% were diagnosed 2+
More informationPotpourri: Cardio-Oncology Cases
Potpourri: Cardio-Oncology Cases Judy Hung, MD Massachusetts General Hospital Harvard Medical School No disclosures; Thank Michael Picard and Tomas Neilan for cases 59 year old woman (sister diagnosed
More informationVECTORS OF CONTRACTION
1/3/216 Strain, Strain Rate, and Torsion: Myocardial Mechanics Simplified and Applied VECTORS OF CONTRACTION John Gorcsan, MD University of Pittsburgh, Pittsburgh, PA Shortening Thickening Twisting No
More informationAnthracycline cardiomypathy in breast cancer: detection and prevention in high-risk patients
Anthracycline cardiomypathy in breast cancer: detection and prevention in high-risk patients Scottish Cancer Trials Breast Group Meeting Thursday 2 nd February 2017 Dr Peter Henriksen Edinburgh Heart Centre
More informationPractice Based Evidence for Treatment of Pregnancy and Anthracycline Cardiomyopathy
Practice Based Evidence for Treatment of Pregnancy and Anthracycline Cardiomyopathy JEAN-BERNARD DURAND, M.D., FCCP, FACC,FACP,FHFSA,FAHA PROFESSOR OF MEDICINE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
More informationCardioOncology: The Promise and Pitfalls of Personalized Medicine
CardioOncology: The Promise and Pitfalls of Personalized Medicine Vijay U. Rao, MD, PhD, FACC, FASE, FHFSA Franciscan Physician Network Indiana Heart Physicians Director, Franciscan Health Inpatient Heart
More informationChemotherapy- Associated Heart Failure. M. Birhan Yılmaz M.D, FESC Professor of Medicine Department of Cardiology Cumhuriyet University Sivas, TURKEY
Chemotherapy- Associated Heart Failure M. Birhan Yılmaz M.D, FESC Professor of Medicine Department of Cardiology Cumhuriyet University Sivas, TURKEY In last 20 years life-expectancy for patients with cancer
More informationCardiotoxic Effects of Chemotherapy on Pediatric and Adult Survivors of Cancer
Cardiotoxic Effects of Chemotherapy on Pediatric and Adult Survivors of Cancer Dr. Chris Fryer, Pediatric Oncologist, BC Children s Hospital Dr. Sean Virani, Founding Director, UBC Cardiovascular Oncology
More informationMultiparametric T1, T2 and T2* MR Imaging
Multiparametric T1, T2 and T2* MR Imaging Kate Hanneman MD Assistant Professor of Radiology Joint Department of Medical Imaging, University of Toronto Disclosure Neither I nor my immediate family members
More informationExpert Consensus for MMI Evaluation of Adult Patients During and After Cancer Rx
Expert Consensus for MMI Evaluation of Adult Patients During and After Cancer Rx 5 th Annual Echo Florida, October 2016 Vincent L. Sorrell, MD Anthony N. DeMaria Professor of Medicine (Card/ Rad) University
More informationCardiotoxicity: The View of the Cardiologist
Cardiotoxicity: The View of the Cardiologist Dr. Yael Peled, Cardio-Oncology Interactions: 1.Cardiotoxicity following chemotherapy 2. Co existence of cancer and CVD Aging & common risk factors cardiac
More informationImaging and heart failure
Imaging and heart failure Jeroen J Bax Dept of Cardiology Leiden Univ Medical Center The Netherlands Davos, feb 2013 Research grants: Medtronic, Biotronik, Boston, St Jude, BMS imaging, GE Healthcare,
More informationΜυοκαρδιοπάθεια από τη θεραπεία του καρκίνου. Δημήτρης Φαρμάκης Ιατρική Σχολή ΕΚΠΑ Αθήνα
Μυοκαρδιοπάθεια από τη θεραπεία του καρκίνου Δημήτρης Φαρμάκης Ιατρική Σχολή ΕΚΠΑ Αθήνα Estimated and projected cancer survivors in USA de Moor JS et al. Cancer Epidemiol Biomarkers Prev 2013 Causes of
More informationExpert Consensus for MMI Evaluation of Adult Patients During and After Cancer Rx. No Real or Potential Conflict of Interests for this Talk CTRCD
Expert Consensus for MMI Evaluation of Adult Patients During and After Cancer Rx Vincent L. Sorrell, MD Anthony N. DeMaria Professor of Medicine University of Kentucky / Gill Heart & Vascular Institute
More informationIan Paterson, Mazankowski Alberta Heart Institute Division of Cardiology, University of Alberta
Ian Paterson, Mazankowski Alberta Heart Institute Division of Cardiology, University of Alberta Peer Reviewed Funding: CIHR, ACF, AI-HS Industry: Servier Canada Inc, RocheCanada Inc. What is your approach
More informationTissue Doppler and Strain Imaging
Tissue Doppler and Strain Imaging Steven J. Lester MD, FRCP(C), FACC, FASE Relevant Financial Relationship(s) None Off Label Usage None 1 Objective way with which to quantify the minor amplitude and temporal
More informationManaging LV Impairment with Cancer Therapies
British Society for Heart Failure Revalidation & Training Day London, March 2017 Managing LV Impairment with Cancer Therapies Zaheer Yousef BSc MBBS MD FESC FRCP Heart Muscle Diseases & Heart Function
More informationCardiac magnetic resonance imaging in rheumatoid arthritis: promising or misleading? Sophie Mavrogeni MD FESC
Cardiac magnetic resonance imaging in rheumatoid arthritis: promising or misleading? Sophie Mavrogeni MD FESC Onassis Cardiac Surgery Center Athens Greece Nothing to disclose Financial disclosure Cardiac
More informationCardio-Oncology at MHI. Kasia Hryniewicz, M.D.
Minneapolis Heart Institute at Abbott Northwestern Hospital Cardio-Oncology at MHI Cardiovascular Nursing Conference Kasia Hryniewicz, M.D. October 7 th, 2015 No disclosure 1 Why cardio-oncology? Background
More informationClinical Policy Title: Echocardiographic assessment of myocardial strain for cancer patients
Clinical Policy Title: Echocardiographic assessment of myocardial strain for cancer patients Clinical Policy Number: 04.01.07 Effective Date: April 1, 2016 Initial Review Date: November 18, 2015 Most Recent
More informationNew Cardiac Guidelines Where They Agree, Where They Differ, and How Does It Affect Patient Care
New Cardiac Guidelines Where They Agree, Where They Differ, and How Does It Affect Patient Care Sandra M Swain, MD, FACP, FASCO Professor of Medicine Associate Dean for Research Development Georgetown
More informationA Light in the Dark: Cardiac MRI and Risk Mitigation. J. Ronald Mikolich MD Professor of Internal Medicine Northeast Ohio Medical University (NEOMED)
A Light in the Dark: Cardiac MRI and Risk Mitigation J. Ronald Mikolich MD Professor of Internal Medicine Northeast Ohio Medical University (NEOMED) Dr. Mikolich has NO financial disclosures relative to
More informationTissue Doppler and Strain Imaging
Tissue Doppler and Strain Imaging Steven J. Lester MD, FRCP(C), FACC, FASE Relevant Financial Relationship(s) None Off Label Usage None 1 Objective way with which to quantify the minor amplitude and temporal
More informationCardiology for the Practitioner Advanced Cardiac Imaging: Worth the pretty pictures?
Keenan Research Centre Li Ka Shing Knowledge Institute Cardiology for the Practitioner Advanced Cardiac Imaging: Worth the pretty pictures? Howard Leong-Poi, MD, FRCPC Associate Professor of Medicine St.
More informationStrain and Strain Rate Imaging How, Why and When?
Strain and Strain Rate Imaging How, Why and When? João L. Cavalcante, MD Advanced Cardiac Imaging Fellow Cleveland Clinic Foundation Disclosures: No conflicts of interest Movement vs Deformation Movement
More informationCardiac Health in Duchenne: What we are Learning from Cardiac MRI
Cardiac Health in Duchenne: What we are Learning from Cardiac MRI 24 th Annual Duchenne Connect Conference Parent Project Muscular Dystrophy Scottsdale, AZ June 29, 2018 Kan N. Hor, MD Director of Cardiac
More informationWhat s New in Cardiac MRI
What s New in Cardiac MRI Katie M. Hawthorne, MD Director, Cardiac MRI Main Line Health Philadelphia Cardiovascular Summit November 18, 2017 Cardiac MRI: Disclosure 2 Disclosures No financial disclosures
More informationCardiovascular outcomes in survivors of childhood cancer
Cardiovascular outcomes in survivors of childhood cancer Paul Nathan MD, MSc Director, AfterCare Program Division of Haematology/Oncology The Hospital for Sick Children, Toronto Conflicts Nothing to declare
More informationClinical Perspective: How Are We Doing From a Clinician s Point of View
Clinical Perspective: How Are We Doing From a Clinician s Point of View Steven E. Lipshultz, MD Department of Pediatrics University of Miami Miller School of Medicine Holtz Children s Hospital of the University
More informationIt s not just the chemo a case of exertional dyspnoea in a Hodgkin survivor.
It s not just the chemo a case of exertional dyspnoea in a Hodgkin survivor. V Aggelis 1 MRCP M Westwood 1,2 MBBS MD FRCP FESC G Lloyd 1 MBBS MD FRCP S Hallam 3 MA PhD MRCP FRCPath AK Ghosh 1,2 MBBS MRCP
More informationOutils d évaluation myocardique par relaxométrie (Myomaps)
Cardiovascular sciences Outils d évaluation myocardique par relaxométrie (Myomaps) Alain Nchimi Geva T. Magnetic resonance imaging: historical perspective. J Cardiovasc Magn Reson. 2006;8(4):573-80. CMR
More informationUsefulness of Delayed Enhancement by Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy as a Marker of Disease and Its Severity
Usefulness of Delayed Enhancement by Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy as a Marker of Disease and Its Severity G.D.Aquaro, MD Fondazione G.Monasterio Regione Toscana/CNR Pisa, Italy
More informationValvular Regurgitation: Can We Do Better Than Colour Doppler?
Valvular Regurgitation: Can We Do Better Than Colour Doppler? A/Prof David Prior St Vincent s Hospital Melbourne Sports Cardiology Valvular Regurgitation Valve regurgitation volume loads the ventricles
More informationRECONCILING GUIDELINES, RECOMMENDATIONS AND CONSENSUS STATEMENTS TO PROVIDE OPTIMAL CARDIO-ONCOLOGY CARE
RECONCILING GUIDELINES, RECOMMENDATIONS AND CONSENSUS STATEMENTS TO PROVIDE OPTIMAL CARDIO-ONCOLOGY CARE SARO ARMENIAN, DO, MPH ASSOCIATE PROFESSOR, DEPARTMENTS OF PEDIATRICS AND POPULATION SCIENCES DIRECTOR,
More informationCardiotoxicities of Cancer in Childhood Cancer Survivors
Cardiotoxicities of Cancer in Childhood Cancer Survivors Steven E. Lipshultz, MD Department of Pediatrics Wayne State University School of Medicine Children s Hospital of Michigan Detroit, MI, USA Stages
More informationDiastolic Dysfunction: Hypertension to Hypertrophy to Heart Failure
Diastolic Dysfunction: Hypertension to Hypertrophy to Heart Failure Dr. Shelley Zieroth FRCPC Assistant Professor, Cardiology, University of Manitoba Director of Cardiac Transplant and Heart Failure Clinics
More informationBreast Cancer and the Heart
Breast Cancer and the Heart Anne H. Blaes, M.D., M.S. Associate Professor University of Minnesota Hematology/Oncology Director, Adult Cancer Survivor Clinic No disclosures Objectives Discuss cardiac complications
More informationCardiovascular Imaging Stress Echo
Cardiovascular Imaging Stress Echo Theodora A Zaglavara, MD, PhD Cardiac Imaging Department INTERBALKAN MEDICAL CENTER Thessaloniki GREECE Evolution of Stress Echo: From Innovation to a Widely Established
More informationΓυναίκα 67 ετών 2 η μετεγχειρητική ημέρα μετά αφαίρεση μονήρους πνευμονικού όγκου στον άνω λοβό του αριστερού πνεύμονα Οξύ πρόσθιο STEMI
Γυναίκα 67 ετών 2 η μετεγχειρητική ημέρα μετά αφαίρεση μονήρους πνευμονικού όγκου στον άνω λοβό του αριστερού πνεύμονα Οξύ πρόσθιο STEMI Οικογενειακό ιστορικό νεοπλασιών: αρνητικό Σύντομο ατομικό ιστορικό:
More informationCurrent Guidelines for Diagnosis of AMI Chest pain ST change on EKG Cardiac Enzymes
Noninvasive Cardiac Imaging in Myocardial Infarction Sangchol Lee Sungkyunkwan University Samsung Medical Center Current Guidelines for Diagnosis of AMI Chest pain ST change on EKG Cardiac Enzymes Do We
More informationPrevention and monitoring of cardiac dysfunction in survivors of adult cancers: ASCO Clinical Practice Guideline
Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: ASCO Clinical Practice Guideline J Clin Oncol. 2016 Dec 5:JCO2016705400. [Epub ahead of print] Objectives: Improve the quality
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Cardiovascular magnetic resonance for timing pulmonary valve replacement E.Valsangiacomo Buechel University Children s Hospital Zurich Outline Introduction Pulmonary
More informationRoohi Ismail-Khan, MD, MS
Roohi Ismail-Khan, MD, MS Associate Member Department of Breast Oncology H. Lee Moffitt Cancer Center Associate Professor University of South Florida Department of Oncological Sciences September 27, 2018
More informationChildren s Oncology Group Long-Term Follow- Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers. Matt Ehrhardt, MD, MS
Children s Oncology Group Long-Term Follow- Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers Matt Ehrhardt, MD, MS Evidence-Based Guidelines for Childhood Cancer Survivors:
More informationImaging in Heart Failure: A Multimodality Approach. Thomas Ryan, MD
Imaging in Heart Failure: A Multimodality Approach Thomas Ryan, MD Heart Failure HFrEF HFpEF EF50% Lifetime risk 20% Prevalence 6M Americans Societal costs - $30B 50% 5-year survival 1 Systolic
More informationXVth Balkan Congress of Radiology Danubius Hotel Helia, October 2017, Budapest, Hungary
XVth Balkan Congress of Radiology Danubius Hotel Helia, 12-14 October 2017, Budapest, Hungary Ružica Maksimović MRI in Myocarditis Faculty of Medicine, University of Belgrade, Centre for Radiology and
More informationInternational Journal of ChemTech Research CODEN (USA): IJCRGG, ISSN: , ISSN(Online): Vol.11 No.
International Journal of ChemTech Research CODEN (USA): IJCRGG, ISSN: 0974-4290, ISSN(Online):2455-9555 Vol.11 No.03, pp 38-43, 2018 Association between Left Ventricular Global Longitudinal Strain and
More information2019 Qualified Clinical Data Registry (QCDR) Performance Measures
2019 Qualified Clinical Data Registry (QCDR) Performance Measures Description: This document contains the 18 performance measures approved by CMS for inclusion in the 2019 Qualified Clinical Data Registry
More informationAdvanced imaging of the left atrium - strain, CT, 3D, MRI -
Advanced imaging of the left atrium - strain, CT, 3D, MRI - Monica Rosca, MD Carol Davila University of Medicine and Pharmacy, Bucharest, Romania Declaration of interest: I have nothing to declare Case
More informationImaging of cardio-pulmonary treatment related damage. Radiotheraphy and Lung
Imaging of cardio-pulmonary treatment related damage Dr. Andrea Borghesi Dr. Emanuele Gavazzi Department of Radiology 2 University of Brescia Radiotheraphy and Lung The goal of radiation therapy (RT) is
More informationHow to Assess Dyssynchrony
How to Assess Dyssynchrony Otto A. Smiseth, Professor, MD, PhD Oslo University Hospital None Conflicts of interest Cardiac resynchronization therapy effect on mortality Cleland JG et al, N Engl J Med
More informationWhat the Cardiologist needs to know from Medical Images
What the Cardiologist needs to know from Medical Images Gerald Maurer Department of Cardiology Medical University of Vienna What kinds of Cardiologists Plumbers Electricians Photographers And then there
More informationImportance of CRT team for optimization of the results: a European point of view
Importance of CRT team for optimization of the results: a European point of view Matteo Bertini, MD, PhD Arcispedale S. Anna Azienda Ospedaliero-Universitaria Cona-Ferrara No conflict of interest to declare
More informationWhy Cardiac MRI? Presented by:
Why Cardiac MRI? Presented by: Lisa G. Carkner, MD, FACC 1 Disclosures I have no financial disclosures Objectives Review basic principles of Cardiac MRI. What patient characteristics do I need to consider
More informationWhen is strain assessment mandatory?
When is strain assessment mandatory? Geneviève Derumeaux University of Lyon France Presenter Disclosure Information Geneviève Derumeaux When is strain assessment mandatory? DISCLOSURE INFORMATION: None
More information17 th Annual Benjamin Schuster, MD Colloquium February 22 nd, 2017:
17 th Annual Benjamin Schuster, MD Colloquium February 22 nd, 2017: Cardiovascular Oncology in 2017: Radiation induced CV Disease Survivorship John Groarke MBBCh MSc MPH Instructor of Medicine, Harvard
More informationThe Road to Improve Cardiovascular Health after Cancer. S. Carolina Masri, MD Cardiology Division University of Washington, Seattle June 2 nd 2018
The Road to Improve Cardiovascular Health after Cancer S. Carolina Masri, MD Cardiology Division University of Washington, Seattle June 2 nd 2018 Objective What are the cardiac complications in cancer
More informationRight ventricular adaptation in endurance athletes. António Freitas. No conflict of interest
The role of echocardiography in sports cardiology Right ventricular adaptation in endurance athletes. António Freitas Cardiology Department - Fernando Fonseca Hospital Lisbon Sports Medicine Centre - Lisbon
More informationRevascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing
Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing Evidence and Uncertainties Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine
More informationΝεότερα ςτην Υπερηχοκαρδιογραφία. Βαςίλειοσ Καμπερίδησ Clinical research fellow in Cardiology
Νεότερα ςτην Υπερηχοκαρδιογραφία Βαςίλειοσ Καμπερίδησ Clinical research fellow in Cardiology Disclosures ESC training grant EACVI research grant HCS training grant ELIKAR research grant Evolution of Echocardiography
More informationFunctional aspects of anatomical imaging techniques
Functional aspects of anatomical imaging techniques Nilendu Purandare Associate Professor & Consultant Radiologist Tata Memorial Centre Functional/metabolic/molecular imaging (radioisotope scanning) PET
More informationAdvanced Cardiac Imaging in Heart Failure Echo and MRI Beyond the LVEF
West Virginia Am Coll Cardiol Sci Sessions, April, 2016 Advanced Cardiac Imaging in Heart Failure Echo and MRI Beyond the LVEF Vincent L. Sorrell, MD DeMaria Professor of Medicine (Card/ Rad) University
More informationHow To Perform Strain Imaging; Step By Step Approach. Maryam Bo Khamseen Echotechnoligist II EACVI, ARDMS, RCS King Abdulaziz Cardiac Center- Riyadh
How To Perform Strain Imaging; Step By Step Approach Maryam Bo Khamseen Echotechnoligist II EACVI, ARDMS, RCS King Abdulaziz Cardiac Center- Riyadh Outlines: Introduction Describe the basic of myocardium
More informationAssessment of Ischemia and Viability
EAE Teaching Course Bucharest, 2010 Assessment of Ischemia and Viability Jens-Uwe Voigt Dpt. of Cardiology University Leuven Belgium Assessment of Ischemia & Viability resting wall motion Stress Testing
More informationCardiac Stress MRI: Detection of Ischemia. Disclosures: Dobutamine Stress MR. April 28, 2018
Cardiac MRI: Detection of Ischemia Cardiac MRI in Today s Clinical Practice Foundations of Cardiovascular Magnetic Resonance Daniel C. Lee, MD, MSc Assistant Professor of Medicine and Radiology Co-Director,
More informationThe best from Euro-Echo Ischemic heart disease. Fausto Rigo,FESC Department of Cardiology Mestre-Venezia Hospital,Italy
The best from Euro-Echo 2011 Ischemic heart disease Fausto Rigo,FESC Department of Cardiology Mestre-Venezia Hospital,Italy faustorigo@alice.it DECLARATION OF CONFLICT OF INTEREST No conflict of interest
More information10/7/2013. Systolic Function How to Measure, How Accurate is Echo, Role of Contrast. Thanks to our Course Director: Neil J.
Systolic Function How to Measure, How Accurate is Echo, Role of Contrast Neil J. Weissman, MD MedStar Health Research Institute & Professor of Medicine Georgetown University Washington, D.C. No Disclosures
More informationDo we have to change our anti-cancer strategy in case of cardiac toxicity? Guy Jerusalem, MD, PhD
Do we have to change our anti-cancer strategy in case of cardiac toxicity? Point of view of the oncologist Guy Jerusalem, MD, PhD CHU Sart Tilman Liège Anticancer therapy: cardiac toxicity New anticancer
More informationAdvanced MR Imaging in Myocarditis
Naeem Merchant MD FRCP Professor of Medicine Department of Radiology Department of Cardiac Sciences Cumming School of Medicine University of Calgary Advanced MR Imaging in Myocarditis The Lake Louise Criteria
More informationA Light in the Dark: Cardiac MRI and Risk Mitigation. J. Ronald Mikolich MD Professor of Internal Medicine Northeast Ohio Medical University (NEOMED)
A Light in the Dark: Cardiac MRI and Risk Mitigation J. Ronald Mikolich MD Professor of Internal Medicine Northeast Ohio Medical University (NEOMED) Dr. Mikolich has NO financial disclosures relative to
More informationTissue Doppler and Strain Imaging. Steven J. Lester MD, FRCP(C), FACC, FASE
Tissue Doppler and Strain Imaging Steven J. Lester MD, FRCP(C), FACC, FASE Relevant Financial Relationship(s) None Off Label Usage None a. Turn the wall filters on and turn down the receiver gain. b. Turn
More informationLoad and Function - Valvular Heart Disease. Tom Marwick, Cardiovascular Imaging Cleveland Clinic
Load and Function - Valvular Heart Disease Tom Marwick, Cardiovascular Imaging Cleveland Clinic Indications for surgery in common valve lesions Risks Operative mortality Failed repair - to MVR Operative
More informationCase Study in Cancer and Cardiotoxicity
Case Study in Cancer and Cardiotoxicity JEAN-BERNARD DURAND, M.D., FCCP, FACC ASSOCIATE PROFESSOR OF MEDICINE MEDICAL DIRECTOR CARDIOMYOPATHY SERVICES UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER HOUSTON,
More informationEjection Fraction in Heart Failure: A Redefinition. Tarek Kashour King Fahad Cardiac Center King Saud University Riyadh, KSA
Ejection Fraction in Heart Failure: A Redefinition Tarek Kashour King Fahad Cardiac Center King Saud University Riyadh, KSA Word of caution!!! Incomplete understanding of a disease process may lead to
More informationStrain imaging in children: from Tissue Doppler to 3 D
Strain imaging in children: from Tissue Doppler to 3 D Mark kk. Friedberg Fi Outline Deformation in the fetus and neonate Deformation in pediatric cardiomyopathy y (briefly!) Deformation in Congenital
More informationTHE NEW PLACE OF CARDIAC MRI IN AERONAUTICAL FITNESS
88 th ASMA ANNUAL SCIENTIFIC MEETING DENVER - CO April 30- May 4, 2017 THE NEW PLACE OF CARDIAC MRI IN AERONAUTICAL FITNESS S. BISCONTE (1), J. MONIN (2), N. HUIBAN (3), G. GUIU (2), S. NGUYEN (1), O.
More informationKlinische Anwendung und neue Entwicklungen: Welches Verfahren für welche Indika:on? Kardiales MR. 17. Zürcher Herzkurs
Klinische Anwendung und neue Entwicklungen: Welches Verfahren für welche Indika:on? Kardiales MR 17. Zürcher Herzkurs 28.09.2017 Dr. med. Gabriella De Pasquale HerzGefässZentrum Zürich Klinik im Park Most
More informationHeart Transplantation is Dead
Heart Transplantation is Dead Alternatives to Transplantation in Heart Failure Sagar Damle, MD University of Colorado Health Sciences Center Grand Rounds September 8, 2008 Outline Why is there a debate?
More informationGlobal left ventricular circumferential strain is a marker for both systolic and diastolic myocardial function
Global left ventricular circumferential strain is a marker for both systolic and diastolic myocardial function Toshinari Onishi 1, Samir K. Saha 2, Daniel Ludwig 1, Erik B. Schelbert 1, David Schwartzman
More information